# US 2016/0256401 A1 · Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256401 A1
- Document ID: US20160256401A1
- Status: Published application
- Kind: A1
- Application number: 15/061,096
- Filed: 2016-03-04
- Published: 2016-09-08
- Earliest claimed: 2011-04-29
- Assignees: Selecta Biosciences, Inc.
- Applicants: Selecta Biosciences, Inc.
- Inventors: Christopher Fraser; Takashi Kei Kishimoto; Roberto A. Maldonado
- Web page: https://patentgrep.com/patent/US20160256401A1

## CPC

- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 9/5115: {Inorganic compounds}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 38/13: Cyclosporins
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/38: Albumins
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 39/35: Allergens
- A61K 39/36: from pollen
- A61K 47/50: the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K 47/52: the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
- A61K 47/544: {Phospholipids}
- A61K 47/593: {Polyesters, e.g. PLGA or polylactide-co-glycolide}
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 47/69: the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/06: Antianaemics
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- G01N 33/505: {involving T-cells}
- G01N 33/56972: {White blood cells}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/577: {tolerising response}
- B82Y 40/00: Manufacture or treatment of nanostructures
- G01N 2333/7051: T-cell receptor (TcR)-CD3 complex
- G01N 2333/70514: CD4
- G01N 2333/70517: CD8
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.

## Claims

### Claim 1

A composition comprising:
(i) a first population of synthetic nanocarriers that are coupled to immunosuppressants, and
(ii) a second population of synthetic nanocarriers that are coupled to therapeutic protein APC presentable antigens.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the first population and second population are the same.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the immunosuppressants comprise a statin, an mTOR inhibitor, a TGF-β signaling agent, a corticosteroid, an inhibitor of mitochondrial function, a P38 inhibitor, an NF-κβ inhibitor, an adenosine receptor agonist, a prostaglandin E2 agonist, a phosphodiesterase 4 inhibitor, an HDAC inhibitor or a proteasome inhibitor.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The composition of claim 1, wherein the therapeutic protein APC presentable antigens comprise MHC Class I-restricted and/or MHC Class II-restricted epitopes of a therapeutic protein.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The composition of claim 1, wherein the therapeutic protein APC presentable antigens comprise B cell epitopes of a therapeutic protein.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the therapeutic protein APC presentable antigens comprise substantially no B cell epitopes of a therapeutic protein.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the therapeutic protein APC presentable antigens comprise a therapeutic protein for protein replacement or protein supplementation therapy, or a fragment thereof.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the therapeutic protein APC presentable antigens comprise a/an infusible or injectable therapeutic protein, enzyme, enzyme cofactor, hormone, blood or blood coagulation factor, cytokine, interferon, growth factor, monoclonal antibody, polyclonal antibody or protein associated with Pompe's disease, or a fragment thereof.

### Claim at position 11

11-18. (canceled)

### Claim 19 (depends on 1)

The composition of claim 1, wherein the load of the immunosuppressant and/or therapeutic protein APC presentable antigen on average across the first and/or second population of synthetic nanocarriers is between 0.0001% and 50%.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The composition of claim 1, wherein the synthetic nanocarriers of the first population and/or second population comprise lipid nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, virus-like particles or peptide or protein particles.

### Claim at position 15

22-31. (canceled)

### Claim 32 (depends on 1)

The composition of claim 1, wherein the mean of a particle size distribution obtained using dynamic light scattering of the synthetic nanocarriers of the first and/or second population is a diameter greater than 100 nm.

### Claim at position 17

33-36. (canceled)

### Claim 37 (depends on 1)

The composition of claim 1, wherein the aspect ratio of the synthetic nanocarriers of the first population and/or second population is greater than 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:5, 1:7 or 1:10.

### Claim 38

(canceled)

### Claim 39 (depends on 1)

A dosage form comprising the composition of claim 1.

### Claim 40 (depends on 1)

A method comprising administering the composition of claim 1 to a subject that is being administered or will be administered a therapeutic protein.

### Claim at position 22

41-55. (canceled)

### Claim 56

A method comprising:
administering to a subject a composition comprising:
(i) a first population of synthetic nanocarriers that are coupled to immunosuppressants, and
(ii) a second population of synthetic nanocarriers that are coupled to therapeutic protein APC presentable antigens,
wherein the composition is in an amount effective to reduce the generation of an undesired immune response against the therapeutic protein APC presentable antigens.

### Claim 57

A method comprising:
reducing the generation of an undesired immune response in a subject by administering a composition comprising:
(i) a first population of synthetic nanocarriers that are coupled to immunosuppressants, and
(ii) a second population of synthetic nanocarriers that are coupled to therapeutic protein APC presentable antigens.

### Claim 58

A method comprising:
administering a composition to a subject according to a protocol that was previously shown to reduce the generation of an undesired immune response to therapeutic protein APC presentable antigens in one or more test subjects;
wherein the composition comprises:
(i) a first population of synthetic nanocarriers that are coupled to immunosuppressants, and
(ii) a second population of synthetic nanocarriers that are coupled to the therapeutic protein APC presentable antigens.

### Claim at position 26

59-103. (canceled)

### Claim 104

A method comprising:
(i) producing a first population of synthetic nanocarriers that are coupled to immunosuppressants, and
(ii) producing a second population of synthetic nanocarriers that are coupled to therapeutic protein APC presentable antigens.

### Claim at position 28

105-110. (canceled)

### Claim 111 (depends on 104)

A process for producing a composition or dosage form comprising:
(i) a first population of synthetic nanocarriers that are coupled to immunosuppressants, and
(ii) a second population of synthetic nanocarriers that are coupled to therapeutic protein APC presentable antigens,
the process comprising the steps as defined in the method of claim 104.

### Claim 112 (depends on 104)

A composition or dosage form obtainable by the method or process of claim 104.

### Claim at position 31

113-116. (canceled)
